Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

About this update from Spectral Medical Inc

[{"type":"text","content":"Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders\n\n\n\n TORONTO, June 06, 2025 (GLOBE NEWSWIRE) --\n \n Spectral Medical Inc.\n \n (\n \n \"Spectral\" or the \"Company\"\n \n )\n \n (TSX: EDT)\n \n , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the \"\n \n Shareholders\n \n \") held yesterday on June 5, 2025 (the \"\n \n Meeting\n \n \"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the \"\n \n Circular\n \n \") to its Shareholders were approved.\n \n\n Results of the matters voted on at the Meeting are set out below.\n \n\n\n\n Election of Directors\n \n\n\n\n Spectral's seven director nominees were elected:\n \n\n\n\n\n Nominee\n \n\n\n\n Votes For (percent)\n \n\n\n\n Votes Withheld (percent)\n \n\n\n\n\n Jan D'Alvise\n \n\n 99.78%\n \n\n\n\n 0.22%\n \n\n\n\n\n\n Jun Hayakawa\n \n\n 99.79%\n \n\n\n\n 0.21%\n \n\n\n\n\n\n Chris Seto\n \n\n 89.39%\n \n\n\n\n 10.61%\n \n\n\n\n\n\n William Stevens\n \n\n 99.50%\n \n\n\n\n 0.50%\n \n\n\n\n\n\n Paul Walker\n \n\n 97.67%\n \n\n\n\n 2.33%\n \n\n\n\n\n\n David W. Feigal, Jr.\n \n\n 99.67%\n \n\n\n\n 0.33%\n \n\n\n\n\n\n Cristiano Franzi\n \n\n 99.78%\n \n\n\n\n 0.22%\n \n\n\n\n\n\n\n\n\n Appointment of Auditors\n \n\n\n\n MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral.\n \n\n Votes For: 99.95%\n \n\n Votes Withheld: 0.05%\n \n\n\n About Spectral\n \n\n\n Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood.\n \n\n PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Des...

More updates from Spectral Medical Inc